You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨信達生物(1801.HK)漲約4% 將發表達伯舒研究結果
格隆匯 09-16 10:09
格隆匯9月16日丨信達生物(1801.HK)漲約4%,報64.6港元,股價再創歷史新高,總市值904億港元。信達生物和禮來製藥(LLY.US)將於9月19日至21日的2020年歐洲腫瘤內科學會(ESMO)年會上,共同宣佈六項關於達伯舒(信迪利單抗注射液)的最新臨牀研究成果。此外,在已獲悉的2020 ESMO會議安排中,達伯舒®共有6項研究入選,包括2項最新突破性摘要(LBA,mini oral)以及4項電子壁報(e-poster),其中包括2項正在進行中的III期研究。研究覆蓋的腫瘤領域包括:肺癌、肝細胞癌、胃癌、婦科腫瘤、其他實體瘤等等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account